Development

Chris Spivey is the editorial director of 

Articles

Decreasing vein to vein time saves lives.

High-titer Vector Producing Cells

Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.

In vivo CAR-T gene therapies could overcome the challenges faced by autologous and allogeneic treatments.

Technology for In Vivo CAR T-cell Therapy Advances

Feliza Mirasol is the science editor for 

An early drug candidate screening strategy should incorporate clear targets to lessen late-stage failure.

Using a Drug Candidate Screening Strategy to Mitigate Late-Stage Risk

Preclinical testing is better able to evaluate complex drug candidates thanks to innovations in animal model approaches.

Animal Models Are Seeing Upgrades to Tackle Complex Molecule Testing

Precision BioSciences has released clinical trial data on CAR T therapy candidates PBCAR0191, PBCAR19B, and PBCAR269A.

Precision BioSciences Releases Data on CAR T Therapy Candidates

Peter Gaskin, PhD, is the senior director of scientific advisory services for Charles River, an AAPS sustaining partner.

To build trust and ensure a high-quality product, companies must be sure their contracts are firm and their lines of communication even firmer.

The Essential Ingredient in any Sponsor-CRO Partnership: Trust

Meg Rivers is the former senior editor for 

New technologies are treatments are emerging to tackle COVID-19 and its assortment of new variants.

The Next Step For COVID-19 Vaccines

Key challenges posed to autologous and allogeneic treatments could be resolved by in-vivo CAR-T gene therapies.

Advances in In Vivo CAR T-cell Therapies

Although mRNA and viral vector vaccines have been top of mind for COVID-19 treatments, other technologies and treatments are emerging—along with new variants. 

What’s Next for COVID-19 Vaccines and Variants? 

Sanofi’s acquisition of Origimm Biotechnology will add to its pipeline of vaccine candidates for treating acne.

Early Phase Development